A Double Blind, Randomized Trial of Alirocumab and Plaque Regression in Peripheral Arterial Disease
Phase of Trial: Phase IV
Latest Information Update: 26 Jul 2017
At a glance
- Drugs Alirocumab (Primary)
- Indications Peripheral arterial disorders
- Focus Therapeutic Use
- 20 Jul 2017 Planned End Date changed from 1 Jun 2020 to 17 Jul 2020.
- 20 Jul 2017 Planned primary completion date changed from 1 Jun 2019 to 17 Jul 2019.
- 20 Jul 2017 Status changed from not yet recruiting to recruiting.